{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:35:45Z","timestamp":1753889745359,"version":"3.41.2"},"reference-count":29,"publisher":"Becaris Publishing Limited","issue":"3","funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            This study evaluates the cost\u2013effectiveness of imipenem\/cilastatin\/relebactam (IMI\/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP\/VABP) in an \u2018early adjustment prescribing scenario\u2019.\n            <jats:bold>Methods:<\/jats:bold>\n            An economic model was constructed to compare two strategies: continuation of empiric piperacillin\/tazobactam (PIP\/TAZ) versus early adjustment to IMI\/REL. A decision tree was used to depict the hospitalization period, and a Markov model used to capture long-term outcomes.\n            <jats:bold>Results:<\/jats:bold>\n            IMI\/REL generated more quality-adjusted life years than PIP\/TAZ, at an increased cost per patient. The incremental cost\u2013effectiveness ratio of $17,529 per QALY is below the typical US willingness-to-pay threshold.\n            <jats:bold>Conclusion:<\/jats:bold>\n            IMI\/REL may represent a cost-effective treatment for payers and a valuable option for clinicians, when considered alongside patient risk factors, local epidemiology, and susceptibility data.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0113","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T13:11:35Z","timestamp":1674479495000},"source":"Crossref","is-referenced-by-count":4,"title":["Cost\u2013effectiveness of imipenem\/cilastatin\/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia"],"prefix":"10.57264","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6581-350X","authenticated-orcid":false,"given":"Jaesh","family":"Naik","sequence":"first","affiliation":[{"name":"BresMed Health Solutions Ltd, Sheffield,S1 2GQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-327X","authenticated-orcid":false,"given":"Ryan","family":"Dillon","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Rahway, NJ\u00a007065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Massello","sequence":"additional","affiliation":[{"name":"BresMed America Inc., Las Vegas, NV\u00a010801, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Ralph","sequence":"additional","affiliation":[{"name":"BresMed Health Solutions Ltd, Sheffield,S1 2GQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-3003","authenticated-orcid":false,"given":"Zhuo","family":"Yang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Rahway, NJ\u00a007065, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_6_2_2","unstructured":"Food and Drug Administration. RECARBRIO. July 2021. Available from: www.merck.com\/product\/usa\/pi_circulars\/r\/recarbrio\/recarbrio_pi.pdf (Accessed: 2 March 2022)."},{"key":"e_1_3_6_3_2","unstructured":"Food and Drug Administration. Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases. August 2017. Available from: www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases"},{"key":"e_1_3_6_4_2","unstructured":"European Medicines Agency. Evaluation of medicinal products indicated for treatment of bacterial infections. Available from: www.ema.europa.eu\/en\/evaluation-medicinal-products-indicated-treatment-bacterial-infections-scientific-guideline"},{"key":"e_1_3_6_5_2","unstructured":"Centers for Disease Control and Prevention. 2019 AR Threats Report. Available from: www.cdc.gov\/drugresistance\/biggest-threats.html"},{"key":"e_1_3_6_6_2","volume-title":"Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics (2018)."},{"issue":"5","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1093\/cid\/cir153","article-title":"Combating antimicrobial resistance: policy recommendations to save lives","volume":"52","author":"Infectious Diseases Society of America (IDSA)","year":"2011","unstructured":"Infectious Diseases Society of America (IDSA) , Spellberg B, Blaser M, Guidos RJ Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52(Suppl. 5), S397\u2013S428 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_6_8_2","first-page":"33","article-title":"Risk factors for Pseudomonas aeruginosa","volume":"14","author":"Merchant S","year":"2018","unstructured":"Merchant S, Proudfoot EM, Quadri HN Risk factors for Pseudomonas aeruginosa. J. Glob. Antimicrob. Resist. 14, 33\u201344 (2018).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12879-015-1123-5","article-title":"Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis","volume":"15","author":"Raman G","year":"2015","unstructured":"Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis. BMC Infect. Dis. 15, 395 (2015).","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"106184","DOI":"10.1016\/j.ijantimicag.2020.106184","article-title":"Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections","volume":"56","author":"Bassetti M","year":"2020","unstructured":"Bassetti M, Rello J, Blasi F Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int. J. Antimicrob. Agents 56(6), 106184 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_6_11_2","unstructured":"Institute for Clinical and Economic Review (ICER). ICER's Reference Case for Economic Evaluations: Principles and Rationale. 31 January 2020. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Reference_Case_013120.pdf (Accessed: 26 May 2021)."},{"issue":"11","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov I","year":"2021","unstructured":"Titov I, Wunderink RG, Roquilly A A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin. Infect. Dis. 73(11), e4539\u2013e4548 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_6_13_2","unstructured":"Study for Monitoring Antimicrobial Resistance Trends (SMART). Merck & Co. Inc NJ USA (2019)."},{"key":"e_1_3_6_14_2","volume-title":"ISPOR 18th Annual European Congress","author":"Prabhu V","year":"2015","unstructured":"Prabhu V, Sen S, Miller B, Basu A, Medic G. Using an economic model to choose initial appropriate antibiotic therapy based on differences in in-vitro susceptibility to ceftolozane\/tazobactam and piperacillin\/tazobactam. Presented at: ISPOR 18th Annual European Congress. Milan, Italy (2015)."},{"issue":"9","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch J","year":"2020","unstructured":"Motsch J, Murta de Oliveira C, Stus V RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin. Infect. Dis. 70(9), 1799\u20131808 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/SHK.0b013e3181cc0418","article-title":"Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis","volume":"33","author":"Siempos II","year":"2010","unstructured":"Siempos II, Vardakas KZ, Kyriakopoulos CE, Ntaidou TK, Falagas ME. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock 33(6), 590\u2013601 (2010).","journal-title":"Shock"},{"key":"e_1_3_6_17_2","unstructured":"National Vital Statistics Reports. United States Life Tables. 2018. Available from: www.cdc.gov\/nchs\/data\/nvsr\/nvsr69\/nvsr69-12-508.pdf"},{"key":"e_1_3_6_18_2","unstructured":"IBM Microdex. The Red Book Online. 2020. Available from: www.micromedexsolutions.com\/home\/dispatch\/ssl\/true (Accessed: 20 November 2020)."},{"issue":"6","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/01.CCM.0000164543.14619.00","article-title":"Daily cost of an intensive care unit day: the contribution of mechanical ventilation","volume":"33","author":"Dasta JF","year":"2005","unstructured":"Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit. Care Med. 33(6), 1266\u20131271 (2005).","journal-title":"Crit. Care Med."},{"key":"e_1_3_6_20_2","unstructured":"Kaiser Family Foundation. Hospital Adjusted Expenses per Inpatient Day. 2018. Available from: www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22 %22sort%22:%22asc%22%7D# (Accessed: 16 November 2020)."},{"key":"e_1_3_6_21_2","unstructured":"Agency for Health and Research Quality. Healthcare Cost and Utilization Project (HCUP). 2020. Available from: https:\/\/hcupnet.ahrq.gov\/#setup"},{"key":"e_1_3_6_22_2","unstructured":"US Bureau of Labor Statistics. Consumer Price Index. 2020. Available from: www.bls.gov\/cpi\/"},{"key":"e_1_3_6_23_2","unstructured":"Centers for Medicare and Medicaid Services (CMS). Physician's fee schedule. 2020. Available from: www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/index.html (Accessed: 20 November 2020)."},{"key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jgar.2018.02.005","article-title":"Recommendations for methicillin-resistant infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: a systematic literature review and meta-analysis","volume":"14","author":"Whittington MD","year":"2018","unstructured":"Whittington MD, Atherly AJ, Curtis DJ Recommendations for methicillin-resistant infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: a systematic literature review and meta-analysis. J. Glob. Antimicrob. Resist. 14, 33\u201344 (2018).","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"11","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1086\/656591","article-title":"The economic effect of screening orthopaedic surgery patients preoperatively for methicillin-resistant","volume":"31","author":"Lee BY","year":"2010","unstructured":"Lee BY, Wiringa AE, Bailey RR The economic effect of screening orthopaedic surgery patients preoperatively for methicillin-resistant. Infect. Control Hosp. Epidemiol. 31(11), 1130\u20131138 (2010).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"e_1_3_6_26_2","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: an international perspective based on EQ-5D.","author":"Szende A","year":"2014","unstructured":"Szende A, Janssen B, Cabases J. (Eds). Self-reported population health: an international perspective based on EQ-5D. SpringerOpen, The Netherlands (2014)."},{"issue":"1","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"dlaa129","DOI":"10.1093\/jacamr\/dlaa129","article-title":"Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU","volume":"3","author":"Moise PA","year":"2021","unstructured":"Moise PA, Gonzalez M, Alekseeva I Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU. JAC Antimicrob. Resist. 3(1), dlaa129 (2021).","journal-title":"JAC Antimicrob. Resist."},{"issue":"3","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-021-01471-8","article-title":"Imipenem\/cilastatin\/relebactam: a review in Gram-negative bacterial infections","volume":"81","author":"Heo YA","year":"2021","unstructured":"Heo YA. Imipenem\/cilastatin\/relebactam: a review in Gram-negative bacterial infections. Drugs 81(3), 377\u2013388 (2021).","journal-title":"Drugs"},{"issue":"11","key":"e_1_3_6_29_2","first-page":"1130","article-title":"In vitro Staphylococcus aureus","volume":"31","author":"Karlowsky JA","year":"2010","unstructured":"Karlowsky JA, Lob SH, Raddatz J In vitro Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 31(11), 1130\u20131138 (2010).","journal-title":"Infect. Control Hosp. Epidemiol."},{"issue":"12","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","article-title":"Activity of imipenem\/relebactam against activity of imipenem\/relebactam and ceftolozane\/tazobactam against clinical isolates of Gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes-study for monitoring antimicrobial resistance trends, United States 2015\u20132017","volume":"72","author":"Karlowsky JA","year":"2021","unstructured":"Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of imipenem\/relebactam against activity of imipenem\/relebactam and ceftolozane\/tazobactam against clinical isolates of Gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes-study for monitoring antimicrobial resistance trends, United States 2015\u20132017. Clin. Infect. Dis. 72(12), 2112\u20132120 (2021).","journal-title":"Clin. Infect. Dis."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2022-0113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:16:39Z","timestamp":1679231799000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.2217\/cer-2022-0113"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0113","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2023,3]]},"article-number":"e220113"}}